Industry Spotlight: Maplight

About Mapligth

Founded in 2019 by award-winning neuroscientists, Maplight is combining novel therapeutics and technologies to treat central nervous system disorders. With a focus on indications with high unmet medical need, MapLight’s initial therapeutics are aimed at safely targeting key symptoms of Autism Spectrum Disorder, Dyskinesia in Parkinson’s Disease, and Schizophrenia.

MapLight’s discovery platform combines three key technologies: Optogenetics, to identify the function of key cell types in the brain; Transcriptomics, provide potential therapeutic targets within those cells; and STARmap to help visualize the targets in brain neural circuits.

ML-004 in Adolescents and Adults With Autism Spectrum Disorders

MapLight Therapeutics is recruiting patients for IRIS, a Phase 2 clinical trial evaluating ML-004, the company’s lead clinical compound for patients with Autism Spectrum Disorder. The study will assess whether there is an impact of ML-004 treatment on the core social communication deficits and on the associated features of irritability in ASD.

The randomized, double blind, placebo-controlled study will evaluate the efficacy and safety profile of ML-004 in up to 150 adults and adolescents with ASD. The study will be conducted in the United States, Australia, and Canada, and is fully funded by MapLight.

For more details on the study, and to contact participating sites near you, visit the study page at